Weekly Digest – September 2026 Weekly Digest – September 2026 18 September 2026: Enhertu receives CHMP recommendation for adjuvant treatment of HER2-positive early Breast cancer Daiichi Sankyo and AstraZeneca announced that Enhertu has been recommended by the EMA’s CHMP for […]
Weekly Digest – September 2026 Weekly Digest – September 2026 18 September 2026: PADCEV + Keytruda receives positive CHMP opinion for resectable MIBC Astellas and MSD announced that PADCEV in combination with KEYTRUDA received a positive CHMP opinion for perioperative […]
Weekly Digest – September 2026 Weekly Digest – September 2026 23 September 2026: SOTIO advances SOT106 with dual FDA designations for Sarcoma SOTIO announced that SOT106 received two additional FDA designations: Orphan Drug Designation for soft tissue sarcoma and Fast […]
Weekly Digest – September 2026 Weekly Digest – September 2026 22 September 2026: Iza-bren granted BTD in China for the treatment of mTNBC Biokin announced that Iza-bren, its first-in-class EGFR×HER3 bispecific ADC, has received China NMPA Breakthrough Therapy Designation for […]
Weekly Digest – September 2026 Weekly Digest – September 2026 21 September 2026: Telix and ITM join forces to create a radiopharmaceutical powerhouse Telix Pharmaceuticals announced a strategic agreement to merge with ITM Isotope Technologies Munich, creating a vertically integrated […]
Weekly Digest – September 2026 Weekly Digest – September 2026 22 September 2026: BoomRay enters exclusive global license agreement with Novartis for a novel radioligand therapy asset BoomRay announced an exclusive global license agreement with Novartis for a novel preclinical […]
